556 | Humans (MeSH) |
305 | Germany (MeSH) |
297 | Germany (epidemiology) |
255 | Female (MeSH) |
250 | Male (MeSH) |
221 | Influenza, Human (epidemiology) |
213 | Influenza, Human (prevention & control) |
212 | Adult (MeSH) |
203 | Middle Aged (MeSH) |
165 | Aged (MeSH) |
159 | Adolescent (MeSH) |
152 | Child (MeSH) |
125 | Child, Preschool (MeSH) |
122 | Influenza Vaccines (administration & dosage) |
119 | Animals (MeSH) |
113 | Young Adult (MeSH) |
110 | Infant (MeSH) |
80 | Risk Factors (MeSH) |
76 | Influenza, Human (virology) |
75 | Seasons (MeSH) |
75 | Aged, 80 and over (MeSH) |
58 | Influenza, Human (diagnosis) |
57 | Incidence (MeSH) |
54 | Vaccination (statistics & numerical data) |
52 | Infant, Newborn (MeSH) |
51 | Prevalence (MeSH) |
48 | Influenza Vaccines (immunology) |
47 | Influenza, Human (immunology) |
47 | Influenza A Virus, H1N1 Subtype (MeSH) |
45 | Surveys and Questionnaires (MeSH) |
42 | Influenza in Birds (epidemiology) |
41 | Influenza, Human (transmission) |
40 | Influenza, Human (mortality) |
40 | Cross-Sectional Studies (MeSH) |
39 | Disease Outbreaks (prevention & control) |
39 | Antibodies, Viral (blood) |
39 | Age Factors (MeSH) |
37 | Influenza Vaccines (therapeutic use) |
37 | Disease Outbreaks (MeSH) |
35 | Influenza A virus (isolation & purification) |
33 | Influenza Vaccines (adverse effects) |
32 | Phylogeny (MeSH) |
32 | Influenza in Birds (virology) |
32 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
32 | Influenza A Virus, H1N1 Subtype (immunology) |
31 | Population Surveillance (MeSH) |
31 | Pandemics (MeSH) |
31 | Disease Outbreaks (statistics & numerical data) |
31 | Antiviral Agents (therapeutic use) |
30 | Respiratory Tract Infections (epidemiology) |
30 | Orthomyxoviridae Infections (veterinary) |
29 | Treatment Outcome (MeSH) |
29 | Risk Assessment (MeSH) |
29 | Berlin (MeSH) |
29 | Age Distribution (MeSH) |
27 | Retrospective Studies (MeSH) |
27 | Influenza, Human (drug therapy) |
26 | Vaccination (MeSH) |
26 | Population Surveillance (methods) |
25 | Prospective Studies (MeSH) |
25 | Health Knowledge, Attitudes, Practice (MeSH) |
25 | Disease Outbreaks (veterinary) |
24 | Time Factors (MeSH) |
24 | Practice Guidelines as Topic (MeSH) |
24 | Orthomyxoviridae Infections (epidemiology) |
23 | Swine (MeSH) |
23 | Influenza A virus (genetics) |
21 | Influenza Vaccines (MeSH) |
21 | Attitude of Health Personnel (MeSH) |
20 | Seroepidemiologic Studies (MeSH) |
20 | Respiratory Tract Infections (virology) |
20 | Pregnancy (MeSH) |
20 | Mass Vaccination (statistics & numerical data) |
20 | Influenza, Human (complications) |
20 | Influenza A virus (immunology) |
20 | Influenza A virus (classification) |
20 | Hemagglutination Inhibition Tests (MeSH) |
20 | Birds (MeSH) |
19 | Swine Diseases (virology) |
19 | Pandemics (prevention & control) |
19 | Orthomyxoviridae Infections (virology) |
19 | Health Surveys (MeSH) |
19 | Case-Control Studies (MeSH) |
18 | Influenza, Human (therapy) |
18 | Influenza A Virus, H1N1 Subtype (genetics) |
17 | Sentinel Surveillance (MeSH) |
17 | Sensitivity and Specificity (MeSH) |
17 | Risk Assessment (methods) |
17 | Hospitalization (statistics & numerical data) |
17 | Cross Infection (prevention & control) |
16 | Sex Distribution (MeSH) |
16 | Pandemics (statistics & numerical data) |
16 | Influenza in Birds (transmission) |
16 | Cross Infection (epidemiology) |
15 | Acute Disease (MeSH) |
14 | Swine Diseases (epidemiology) |
14 | Respiratory Tract Infections (diagnosis) |
14 | Influenza, Human (economics) |
14 | Immunization Schedule (MeSH) |
14 | Comorbidity (MeSH) |
14 | Cause of Death (MeSH) |
13 | Molecular Sequence Data (MeSH) |
13 | Influenza A Virus, H5N1 Subtype (isolation & purification) |
13 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
13 | Cohort Studies (MeSH) |
12 | Vaccination (standards) |
12 | Vaccination (methods) |
12 | Travel (MeSH) |
12 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
12 | Pneumococcal Vaccines (administration & dosage) |
12 | Patient Acceptance of Health Care (statistics & numerical data) |
12 | Neuraminidase (genetics) |
12 | Neuraminidase (antagonists & inhibitors) |
12 | Influenza, Human (history) |
12 | Influenza B virus (isolation & purification) |
12 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
12 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
12 | History, 20th Century (MeSH) |
12 | Anti-Bacterial Agents (therapeutic use) |
11 | Viruses (isolation & purification) |
11 | Virus Diseases (epidemiology) |
11 | Vaccination (psychology) |
11 | Oseltamivir (therapeutic use) |
11 | Models, Statistical (MeSH) |
11 | Logistic Models (MeSH) |
11 | Influenza, Human (nursing) |
11 | Influenza Vaccines (supply & distribution) |
11 | Influenza A virus (pathogenicity) |
11 | Influenza A Virus, H3N2 Subtype (immunology) |
11 | Genetic Variation (MeSH) |
11 | Cost-Benefit Analysis (MeSH) |
10 | Vaccination (adverse effects) |
10 | Survival Rate (MeSH) |
10 | Survival Analysis (MeSH) |
10 | Respiratory Syncytial Virus Infections (epidemiology) |
10 | Pneumococcal Vaccines (MeSH) |
10 | Pneumococcal Infections (prevention & control) |
10 | Netherlands (epidemiology) |
10 | Influenza, Human (pathology) |
10 | Influenza, Human (MeSH) |
10 | Influenza Vaccines (economics) |
10 | Influenza B virus (immunology) |
10 | Influenza A virus (MeSH) |
10 | Influenza A Virus, H3N2 Subtype (genetics) |
10 | Hospitals, University (MeSH) |
10 | Cost of Illness (MeSH) |
10 | Communicable Diseases (epidemiology) |
10 | Animals, Wild (MeSH) |
9 | World Health Organization (MeSH) |
9 | Reassortant Viruses (genetics) |
9 | Models, Theoretical (MeSH) |
9 | Immunization, Secondary (MeSH) |
9 | Immunization Programs (statistics & numerical data) |
9 | Hospitalization (MeSH) |
9 | Health Personnel (MeSH) |
9 | Forecasting (MeSH) |
9 | Europe (MeSH) |
9 | Diagnosis, Differential (MeSH) |
9 | Communicable Disease Control (organization & administration) |
9 | Birds (virology) |
9 | Animals, Wild (virology) |
8 | Vaccination (trends) |
8 | Switzerland (epidemiology) |
8 | Sequence Analysis, DNA (MeSH) |
8 | Risk (MeSH) |
8 | Reproducibility of Results (MeSH) |
8 | Poultry (MeSH) |
8 | Polymerase Chain Reaction (MeSH) |
8 | Patient Education as Topic (MeSH) |
8 | Orthomyxoviridae (immunology) |
8 | Occupational Diseases (prevention & control) |
8 | Nasopharynx (virology) |
8 | Medical Staff, Hospital (statistics & numerical data) |
8 | Interviews as Topic (MeSH) |
8 | Influenza in Birds (pathology) |
8 | Influenza Vaccines (standards) |
8 | Influenza A Virus, H5N1 Subtype (genetics) |
8 | Influenza A Virus, H1N1 Subtype (classification) |
8 | Immunization Programs (MeSH) |
8 | Germany, West (MeSH) |
8 | Family Characteristics (MeSH) |
8 | Epidemics (MeSH) |
8 | Cross Infection (transmission) |
8 | Chickens (MeSH) |
8 | Base Sequence (MeSH) |
8 | Antiviral Agents (pharmacology) |
7 | Virus Diseases (virology) |
7 | Virus Diseases (diagnosis) |
7 | Virulence (MeSH) |
7 | Vaccination (legislation & jurisprudence) |
7 | United States (epidemiology) |
7 | United States (MeSH) |
7 | Sex Factors (MeSH) |
7 | Reverse Transcriptase Polymerase Chain Reaction (methods) |
7 | RNA, Viral (genetics) |
7 | Paramyxoviridae Infections (epidemiology) |
7 | Orthomyxoviridae (isolation & purification) |
7 | Orthomyxoviridae (MeSH) |
7 | Italy (epidemiology) |
7 | Internet (MeSH) |
7 | Influenza, Human (psychology) |
7 | Influenza, Human (blood) |
7 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
7 | Infectious Disease Transmission, Professional-to-Patient (prevention & control) |
7 | Germany, East (MeSH) |
7 | Dogs (MeSH) |
7 | Computer Simulation (MeSH) |
7 | Community-Acquired Infections (epidemiology) |
7 | Communicable Diseases, Emerging (epidemiology) |
7 | Communicable Disease Control (methods) |
7 | Cats (MeSH) |
7 | Berlin (epidemiology) |
7 | Antigens, Viral (immunology) |
7 | Amino Acid Sequence (MeSH) |
6 | Virology (methods) |
6 | Viral Vaccines (administration & dosage) |
6 | Utilization Review (MeSH) |
6 | Species Specificity (MeSH) |
6 | Severity of Illness Index (MeSH) |
6 | Respiratory Syncytial Virus Infections (virology) |
6 | Real-Time Polymerase Chain Reaction (MeSH) |
6 | RNA, Viral (analysis) |
6 | Public Health (MeSH) |
6 | Poultry Diseases (virology) |
6 | Poultry Diseases (epidemiology) |
6 | Poultry (virology) |
6 | Pneumonia, Viral (diagnosis) |
6 | Orthomyxoviridae Infections (immunology) |
6 | Orthomyxoviridae (classification) |
6 | Mass Vaccination (standards) |
6 | Mass Vaccination (methods) |
6 | Influenza, Human (physiopathology) |
6 | Influenza in Birds (prevention & control) |
6 | Influenza A Virus, H5N1 Subtype (MeSH) |
6 | Hygiene (MeSH) |
6 | Health Care Surveys (MeSH) |
6 | Guideline Adherence (MeSH) |
6 | France (epidemiology) |
6 | Follow-Up Studies (MeSH) |
6 | European Union (MeSH) |
6 | Drug Resistance, Viral (MeSH) |
6 | Data Collection (MeSH) |
6 | Cross Infection (mortality) |
6 | Cluster Analysis (MeSH) |
6 | Chick Embryo (MeSH) |
6 | Austria (epidemiology) |
6 | Antibody Formation (immunology) |
6 | Absenteeism (MeSH) |
5 | Zoonoses (MeSH) |
5 | Whooping Cough (prevention & control) |
5 | Vaccination (economics) |
5 | United Kingdom (epidemiology) |
5 | Telephone (MeSH) |
5 | Quality-Adjusted Life Years (MeSH) |
5 | Prognosis (MeSH) |
5 | Primary Health Care (MeSH) |
5 | Polymerase Chain Reaction (methods) |
5 | Pneumonia, Viral (mortality) |
5 | Pneumococcal Infections (epidemiology) |
5 | Pilot Projects (MeSH) |
5 | Pharynx (virology) |
5 | Patient Compliance (statistics & numerical data) |
5 | Patient Acceptance of Health Care (MeSH) |
5 | Pandemics (history) |
5 | Oseltamivir (pharmacology) |
5 | Odds Ratio (MeSH) |
5 | Occupational Diseases (epidemiology) |
5 | National Health Programs (MeSH) |
5 | Multiplex Polymerase Chain Reaction (MeSH) |
5 | Mortality (trends) |
5 | Models, Biological (MeSH) |
5 | Mass Vaccination (trends) |
5 | Mass Vaccination (organization & administration) |
5 | Mass Vaccination (MeSH) |
5 | Influenza, Human (etiology) |
5 | Influenza B virus (genetics) |
5 | Influenza A virus (drug effects) |
5 | Influenza A Virus, H3N2 Subtype (drug effects) |
5 | Influenza A Virus, H3N2 Subtype (classification) |
5 | Influenza A Virus, H3N2 Subtype (MeSH) |
5 | Influenza A Virus, H1N1 Subtype (physiology) |
5 | Influenza A Virus, H1N1 Subtype (drug effects) |
5 | Hospitals (MeSH) |
5 | Horses (MeSH) |
5 | Health Status (MeSH) |
5 | Health Promotion (statistics & numerical data) |
5 | Health Personnel (statistics & numerical data) |
5 | Guideline Adherence (statistics & numerical data) |
5 | Genotype (MeSH) |
5 | Family Health (MeSH) |
5 | Ducks (virology) |
5 | Disease Outbreaks (history) |
5 | Disaster Planning (organization & administration) |
5 | Databases, Factual (MeSH) |
5 | Cross Infection (virology) |
5 | Community-Acquired Infections (diagnosis) |
5 | Communicable Disease Control (statistics & numerical data) |
5 | Cloaca (virology) |
5 | Cell Line (MeSH) |
5 | Cat Diseases (epidemiology) |
5 | Bird Diseases (virology) |
5 | Bird Diseases (epidemiology) |
5 | Belgium (epidemiology) |
5 | Austria (MeSH) |
5 | Antiviral Agents (administration & dosage) |
5 | Amino Acid Substitution (MeSH) |
5 | Adjuvants, Immunologic (adverse effects) |
5 | Adjuvants, Immunologic (administration & dosage) |
4 | Zanamivir (pharmacology) |
4 | Viruses (genetics) |
4 | Virus Shedding (MeSH) |
4 | Vaccines, Inactivated (immunology) |
4 | Vaccines, Combined (administration & dosage) |
4 | Vaccines, Attenuated (administration & dosage) |
4 | Vaccines (administration & dosage) |
4 | Turkeys (virology) |
4 | Trachea (virology) |
4 | Tetanus Toxoid (administration & dosage) |
4 | Temperature (MeSH) |
4 | Swine (virology) |
4 | Serologic Tests (MeSH) |
4 | Sequence Alignment (MeSH) |
4 | Sentinel Surveillance (veterinary) |
4 | Safety (MeSH) |
4 | Risk Management (methods) |
4 | Reverse Transcriptase Polymerase Chain Reaction (veterinary) |
4 | Respiratory Tract Diseases (epidemiology) |
4 | Registries (MeSH) |
4 | Public Opinion (MeSH) |
4 | Primary Health Care (statistics & numerical data) |
4 | Practice Patterns, Physicians' (MeSH) |
4 | Poultry Diseases (prevention & control) |
4 | Portugal (epidemiology) |
4 | Population Density (MeSH) |
4 | Polymerase Chain Reaction (veterinary) |
4 | Pneumonia, Pneumococcal (prevention & control) |
4 | Pneumonia (epidemiology) |
4 | Physician's Role (MeSH) |
4 | Particle Size (MeSH) |
4 | Orthomyxoviridae Infections (transmission) |
4 | Netherlands (MeSH) |
4 | Mutation (MeSH) |
4 | Molecular Diagnostic Techniques (methods) |
4 | Models, Organizational (MeSH) |
4 | Microbial Sensitivity Tests (MeSH) |
4 | Internationality (MeSH) |
4 | Influenza, Human (classification) |
4 | Influenza in Birds (diagnosis) |
4 | Influenza A Virus, H5N1 Subtype (classification) |
4 | Influenza A Virus, H1N2 Subtype (isolation & purification) |
4 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
4 | Immunoglobulin G (blood) |
4 | Horse Diseases (epidemiology) |
4 | Hemagglutination Inhibition Tests (veterinary) |
4 | Health Promotion (methods) |
4 | Health Policy (MeSH) |
4 | Health Care Costs (MeSH) |
4 | Health Behavior (MeSH) |
4 | Haemophilus Vaccines (administration & dosage) |
4 | Global Health (MeSH) |
4 | Genome, Viral (MeSH) |
4 | Genes, Viral (MeSH) |
4 | General Practice (MeSH) |
4 | France (MeSH) |
4 | Feces (virology) |
4 | Evidence-Based Medicine (MeSH) |
4 | Epidemiological Monitoring (MeSH) |
4 | Enzyme-Linked Immunosorbent Assay (veterinary) |
4 | Dog Diseases (epidemiology) |
4 | Disease Notification (statistics & numerical data) |
4 | Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage) |
4 | Cross Reactions (MeSH) |
4 | Cross Infection (diagnosis) |
4 | Critical Care (MeSH) |
4 | Complement Fixation Tests (MeSH) |
4 | Community-Acquired Infections (mortality) |
4 | Community-Acquired Infections (drug therapy) |
4 | Communicable Diseases, Emerging (virology) |
4 | Communicable Diseases, Emerging (veterinary) |
4 | Communicable Disease Control (standards) |
4 | Coinfection (virology) |
4 | Cardiovascular Diseases (mortality) |
4 | Bacterial Vaccines (administration & dosage) |
4 | Bacterial Infections (microbiology) |
4 | Bacteria (isolation & purification) |
4 | Attitude to Health (MeSH) |
4 | Antigens, Viral (genetics) |
4 | Antibodies, Viral (immunology) |
4 | Antibodies, Bacterial (blood) |
4 | Acute Disease (epidemiology) |
3 | Zoonoses (virology) |
3 | Zoonoses (transmission) |
3 | Zanamivir (therapeutic use) |
3 | World War I (MeSH) |
3 | Virus Diseases (veterinary) |
3 | Virus Diseases (therapy) |
3 | Virus Diseases (prevention & control) |
3 | Virus Cultivation (methods) |
3 | Viral Proteins (genetics) |
3 | Viral Matrix Proteins (genetics) |
3 | Viral Load (MeSH) |
3 | Vaccines, Inactivated (adverse effects) |
3 | Vaccines, Inactivated (administration & dosage) |
3 | Vaccines, Combined (immunology) |
3 | Vaccines, Attenuated (standards) |
3 | Vaccination (ethics) |
3 | Travel (statistics & numerical data) |
3 | Tetanus (prevention & control) |
3 | Tertiary Care Centers (MeSH) |
3 | Swine Diseases (transmission) |
3 | Sweden (epidemiology) |
3 | Spain (epidemiology) |
3 | Societies (MeSH) |
3 | Serotyping (MeSH) |
3 | Sequence Homology (MeSH) |
3 | Self Report (MeSH) |
3 | Rotavirus Vaccines (administration & dosage) |
3 | Risk Assessment (statistics & numerical data) |
3 | Respiratory Tract Infections (therapy) |
3 | Respiratory Tract Infections (microbiology) |
3 | Respiratory Tract Diseases (mortality) |
3 | Respiratory Syncytial Viruses (isolation & purification) |
3 | Respiratory Syncytial Virus, Human (isolation & purification) |
3 | Respiratory Syncytial Virus Infections (diagnosis) |
3 | Respiration, Artificial (MeSH) |
3 | Residence Characteristics (MeSH) |
3 | Regression Analysis (MeSH) |
3 | Reference Standards (MeSH) |
3 | Reassortant Viruses (isolation & purification) |
3 | Reassortant Viruses (classification) |
3 | Randomized Controlled Trials as Topic (MeSH) |
3 | Quality Control (MeSH) |
3 | Public Health Administration (MeSH) |
3 | Product Surveillance, Postmarketing (MeSH) |
3 | Pregnancy Complications, Infectious (prevention & control) |
3 | Pregnancy Complications, Infectious (epidemiology) |
3 | Practice Patterns, Physicians' (statistics & numerical data) |
3 | Poliovirus Vaccine, Inactivated (immunology) |
3 | Poliovirus Vaccine, Inactivated (administration & dosage) |
3 | Pneumonia, Viral (epidemiology) |
3 | Pneumonia, Viral (drug therapy) |
3 | Pneumonia, Bacterial (mortality) |
3 | Pneumonia, Bacterial (epidemiology) |
3 | Pneumococcal Vaccines (immunology) |
3 | Picornaviridae Infections (epidemiology) |
3 | Pertussis Vaccine (administration & dosage) |
3 | Patient Selection (MeSH) |
3 | Patient Participation (statistics & numerical data) |
3 | Patient Isolation (MeSH) |
3 | Particulate Matter (analysis) |
3 | Paramyxoviridae Infections (virology) |
3 | Papillomavirus Vaccines (administration & dosage) |
3 | Outpatients (MeSH) |
3 | Orthomyxoviridae Infections (prevention & control) |
3 | Orthomyxoviridae (growth & development) |
3 | Orthomyxoviridae (genetics) |
3 | Occupational Exposure (MeSH) |
3 | Nursing Staff, Hospital (statistics & numerical data) |
3 | Newcastle disease virus (isolation & purification) |
3 | Newcastle Disease (epidemiology) |
3 | Neutralization Tests (MeSH) |
3 | Neuraminidase (immunology) |
3 | Neuraminidase (chemistry) |
3 | Nasopharynx (microbiology) |
3 | Narcolepsy (epidemiology) |
3 | Mutation, Missense (MeSH) |
3 | Multivariate Analysis (MeSH) |
3 | Multiple Sclerosis (immunology) |
3 | Multiple Sclerosis (epidemiology) |
3 | Motivation (MeSH) |
3 | Mortality (MeSH) |
3 | Molecular Epidemiology (MeSH) |
3 | Models, Economic (MeSH) |
3 | Models, Econometric (MeSH) |
3 | Mexico (MeSH) |
3 | Metapneumovirus (isolation & purification) |
3 | Medical Staff, Hospital (psychology) |
3 | Meat (virology) |
3 | Mandatory Reporting (MeSH) |
3 | Lung (pathology) |
3 | Length of Stay (MeSH) |
3 | Intensive Care Units (MeSH) |
3 | Information Dissemination (methods) |
3 | Influenza in Birds (mortality) |
3 | Influenza A Virus, H7N7 Subtype (pathogenicity) |
3 | Influenza A Virus, H5N8 Subtype (pathogenicity) |
3 | Influenza A Virus, H5N1 Subtype (immunology) |
3 | Influenza A Virus, H1N2 Subtype (genetics) |
3 | Influenza A Virus, H1N2 Subtype (classification) |
3 | Infection Control (MeSH) |
3 | Immunosuppressive Agents (therapeutic use) |
3 | Immunization Programs (organization & administration) |
3 | Immunization (adverse effects) |
3 | Immunization (MeSH) |
3 | Immune Sera (MeSH) |
3 | Humidity (MeSH) |
3 | History, 19th Century (MeSH) |
3 | Hepatitis B Vaccines (administration & dosage) |
3 | Hemagglutinins, Viral (genetics) |
3 | Hemagglutinins (genetics) |